Alopecia - Pipeline Review, H2 2015

Size: px

Start display at page:

Download "Alopecia - Pipeline Review, H2 2015"

Anabel Ray
6 years ago
Views:

1 Published on Market Research Reports Inc. ( Home > Alopecia - Pipeline Review, H Alopecia - Pipeline Review, H Publication ID: GMD Publication September 30, 2015 Date: Pages: 113 Publisher: Global Markets Direct Countries: Global [1] $2, Publication Type * - Select - Please choose the suitable license type from above. More details are at given under tab "Report License Types" below. Add to cart Diseases [2] Pharma & Healthcare [3] Description:

2 Alopecia - Pipeline Review, H Summary Global Markets Direct s, Alopecia - Pipeline Review, H2 2015, provides an overview of the Alopecia s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Alopecia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Alopecia and special features on late-stage and discontinued projects. Global Markets Direct s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industryspecific third party sources, put together by Global Markets Direct s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Alopecia - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Alopecia and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Alopecia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

3 - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Alopecia pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Alopecia - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Alopecia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Table Of Contents: Table of Contents Table of Contents 2 List of Tables 7 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Alopecia Overview 10 Therapeutics Development 11 Pipeline Products for Alopecia - Overview 11 Pipeline Products for Alopecia - Comparative Analysis 12 Alopecia - Therapeutics under Development by Companies 13 Alopecia - Therapeutics under Investigation by Universities/Institutes 15 Alopecia - Pipeline Products Glance 16 Late Stage Products 16 Clinical Stage Products 17 Early Stage Products 18 Unknown Stage Products 19

4 Alopecia - Products under Development by Companies 20 Alopecia - Products under Investigation by Universities/Institutes 22 Alopecia - Companies Involved in Therapeutics Development 23 Allergan Plc 23 AndroScience Corporation 24 Berg, LLC 25 Bristol-Myers Squibb Company 26 Dong-A Socio Group 27 Follicum AB 28 Histogen, Inc. 29 Hyundai Pharmaceutical Co., Ltd. 30 Kuhnil Pharmaceutical Co., Ltd. 31 Kythera Biopharmaceuticals, Inc. 32 Lee's Pharmaceutical Holdings Limited 33 Panacea Biotec Limited 34 Polichem S.A. 35 R-Tech Ueno, Ltd. 36 RepliCel Life Sciences, Inc. 37 RestorGenex Corporation 38 RXi Pharmaceuticals Corporation 39 SWITCH Biotech LLC 40 Taisho Pharmaceutical Co., Ltd. 41 Tigo GmbH 42 Valeant Pharmaceuticals International, Inc. 43 Vida Therapeutics Inc. 44 Alopecia - Therapeutics Assessment 45 Assessment by Monotherapy Products 45 Assessment by Target 46 Assessment by Mechanism of Action 48 Assessment by Route of Administration 50 Assessment by Molecule Type 52 Drug Profiles 54 abatacept - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 Antibodies to Inhibit Heparanase for Cancer - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57

5 ASCJ-9 - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 bimatoprost - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 BMD Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 BRM Drug Profile 63 Product Description 63 Mechanism of Action 63 R&D Progress 63 calcitriol - Drug Profile 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 CB Drug Profile 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 DHL-HisZnNa - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 diphencyprone - Drug Profile 68 Product Description 68 Mechanism of Action 68 R&D Progress 68 finasteride - Drug Profile 69 Product Description 69 Mechanism of Action 69 R&D Progress 69 finasteride - Drug Profile 70 Product Description 70 Mechanism of Action 70 R&D Progress 70

6 FOL Drug Profile 71 Product Description 71 Mechanism of Action 71 R&D Progress 71 Hair Stimulating Complex (HSC) - Drug Profile 72 Product Description 72 Mechanism of Action 72 R&D Progress 72 HTB Drug Profile 74 Product Description 74 Mechanism of Action 74 R&D Progress 74 interferon beta-1b - Drug Profile 75 Product Description 75 Mechanism of Action 75 R&D Progress 75 KI Drug Profile 76 Product Description 76 Mechanism of Action 76 R&D Progress 76 KI Drug Profile 77 Product Description 77 Mechanism of Action 77 R&D Progress 77 minoxidil - Drug Profile 78 Product Description 78 Mechanism of Action 78 R&D Progress 78 OLX Drug Profile 79 Product Description 79 Mechanism of Action 79 R&D Progress 79 Peptide for Alopecia - Drug Profile 80 Product Description 80 Mechanism of Action 80 R&D Progress 80 PRD Drug Profile 81 Product Description 81 Mechanism of Action 81 R&D Progress 81

7 RCH-01 - Drug Profile 82 Product Description 82 Mechanism of Action 82 R&D Progress 82 Recombinant Proteins to Antagonize IFN-Gamma Receptor for Alopecia Areata and Graft Arteriosclerosis - Drug Profile 84 Product Description 84 Mechanism of Action 84 R&D Progress 84 RES Drug Profile 85 Product Description 85 Mechanism of Action 85 R&D Progress 85 RK Drug Profile 87 Product Description 87 Mechanism of Action 87 R&D Progress 87 setipiprant - Drug Profile 89 Product Description 89 Mechanism of Action 89 R&D Progress 89 SM Drug Profile 90 Product Description 90 Mechanism of Action 90 R&D Progress 90 Small Molecule for Androgenic Alopecia - Drug Profile 91 Product Description 91 Mechanism of Action 91 R&D Progress 91 Small Molecule to Inhibit ALK5 for Alopecia - Drug Profile 92 Product Description 92 Mechanism of Action 92 R&D Progress 92 Small Molecules for Dermatological Disorders - Drug Profile 93 Product Description 93 Mechanism of Action 93 R&D Progress 93 Small Molecules to Activate P2Y5 Receptor for Alopecia - Drug Profile 94 Product Description 94 Mechanism of Action 94

8 R&D Progress 94 VTI-1000 Series - Drug Profile 95 Product Description 95 Mechanism of Action 95 R&D Progress 95 ZK Drug Profile 96 Product Description 96 Mechanism of Action 96 R&D Progress 96 Alopecia - Recent Pipeline Updates 97 Alopecia - Dormant Projects 105 Alopecia - Discontinued Products 108 Alopecia - Product Development Milestones 109 Featured News & Press Releases 109 Oct 26, 2012: Glaucoma Drug Bimatoprost May Be Effective In Treating Alopecia, New Research In FASEB Journal Shows 109 Jul 23, 2012: Berg Pharma Launches Clinical Trial On BPM For Prevention Of Chemotherapyinduced Alopecia 109 Jan 24, 2011: R-Tech Ueno Completes Phase IIa Clinical Study Of RK-023 To Treat Androgenetic Alopecia 109 Oct 06, 2010: Cosmo Reports Positive Results In Alopecia Study With CB Oct 06, 2009: R-Tech Ueno Initiates Early Phase II Clinical Trial For RK Jul 16, 2009: Notification Of The Completion Of Phase I Clinical Study Of RK Appendix 112 Methodology 112 Coverage 112 Secondary Research 112 Primary Research 112 Expert Panel Validation 112 Contact Us 112 Disclaimer 113 List of Tables Number of Products under Development for Alopecia, H Number of Products under Development for Alopecia - Comparative Analysis, H Number of Products under Development by Companies, H Number of Products under Investigation by Universities/Institutes, H Comparative Analysis by Late Stage Development, H Comparative Analysis by Clinical Stage Development, H Comparative Analysis by Early Stage Development, H

9 Comparative Analysis by Unknown Stage Development, H Products under Development by Companies, H Products under Development by Companies, H (Contd..1) 21 Products under Investigation by Universities/Institutes, H Alopecia - Pipeline by Allergan Plc, H Alopecia - Pipeline by AndroScience Corporation, H Alopecia - Pipeline by Berg, LLC, H Alopecia - Pipeline by Bristol-Myers Squibb Company, H Alopecia - Pipeline by Dong-A Socio Group, H Alopecia - Pipeline by Follicum AB, H Alopecia - Pipeline by Histogen, Inc., H Alopecia - Pipeline by Hyundai Pharmaceutical Co., Ltd., H Alopecia - Pipeline by Kuhnil Pharmaceutical Co., Ltd., H Alopecia - Pipeline by Kythera Biopharmaceuticals, Inc., H Alopecia - Pipeline by Lee's Pharmaceutical Holdings Limited, H Alopecia - Pipeline by Panacea Biotec Limited, H Alopecia - Pipeline by Polichem S.A., H Alopecia - Pipeline by R-Tech Ueno, Ltd., H Alopecia - Pipeline by RepliCel Life Sciences, Inc., H Alopecia - Pipeline by RestorGenex Corporation, H Alopecia - Pipeline by RXi Pharmaceuticals Corporation, H Alopecia - Pipeline by SWITCH Biotech LLC, H Alopecia - Pipeline by Taisho Pharmaceutical Co., Ltd., H Alopecia - Pipeline by Tigo GmbH, H Alopecia - Pipeline by Valeant Pharmaceuticals International, Inc., H Alopecia - Pipeline by Vida Therapeutics Inc., H Assessment by Monotherapy Products, H Number of Products by Stage and Target, H Number of Products by Stage and Mechanism of Action, H Number of Products by Stage and Route of Administration, H Number of Products by Stage and Molecule Type, H Alopecia Therapeutics - Recent Pipeline Updates, H Alopecia - Dormant Projects, H Alopecia - Dormant Projects (Contd..1), H Alopecia - Dormant Projects (Contd..2), H Alopecia - Discontinued Products, H List of Figures Number of Products under Development for Alopecia, H Number of Products under Development for Alopecia - Comparative Analysis, H

10 Number of Products under Development by Companies, H Number of Products under Investigation by Universities/Institutes, H Comparative Analysis by Late Stage Development, H Comparative Analysis by Clinical Stage Development, H Comparative Analysis by Early Stage Products, H Assessment by Monotherapy Products, H Number of Products by Top 10 Targets, H Number of Products by Stage and Top 10 Targets, H Number of Products by Top 10 Mechanism of Actions, H Number of Products by Stage and Top 10 Mechanism of Actions, H Number of Products by Top 10 Routes of Administration, H Number of Products by Stage and Top 10 Routes of Administration, H Number of Products by Top 10 Molecule Types, H Number of Products by Stage and Top 10 Molecule Types, H Companies Mentioned: Allergan Plc AndroScience Corporation Berg, LLC Bristol-Myers Squibb Company Dong-A Socio Group Follicum AB Histogen, Inc. Hyundai Pharmaceutical Co., Ltd. Kuhnil Pharmaceutical Co., Ltd. Kythera Biopharmaceuticals, Inc. Lee's Pharmaceutical Holdings Limited Panacea Biotec Limited Polichem S.A. R-Tech Ueno, Ltd. RepliCel Life Sciences, Inc. RestorGenex Corporation RXi Pharmaceuticals Corporation SWITCH Biotech LLC Taisho Pharmaceutical Co., Ltd. Tigo GmbH Valeant Pharmaceuticals International, Inc. Vida Therapeutics Inc. License Types:

11 Single User License (PDF) This license allows for use of a publication by one person. This person may print out a single copy of the publication. This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher. This person cannot share the publication (or any information contained therein) with any other person or persons. Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization. Customers who infringe these license terms are liable for a Global license fee. Site License (PDF)* This license allows for use of a publication by all users within one corporate location, e.g. a regional office. These users may print out a single copy of the publication. These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher. These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased. Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization. Customers who infringe these license terms are liable for a Global license fee. Global License (PDF)* This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company. Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization. These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher. *If Applicable.

12 Source URL: Links [1] [2] [3]

Atreca Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Atreca Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile Atreca Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile The Business Research Store is run by Sector Publishing Intelligence